NAD+ 1g & Tirzepatide's Successor : A United Kingdom Update
The recent interest in NAD+ supplementation, particularly at a high dosage of 1g , continues to build within the United Kingdom pharmaceutical community. Concurrently, attention is directed toward Retatrutide, a novel GLP-1 receptor agonist being viewed by many as a potential advancement to Tirze